Clinical Trials Browser

Terminated × rilotumumab × Clear all

NCT00791154 2024-08-23

SCLC

Phase 1/2 Terminated

213 enrolled 16 charts

Lung Neoplasms, Pleural Effusion, Malignant, Small Cell Lung Carcinoma

NCT02926638 2020-03-19

Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Phase 2/3 Terminated

9 enrolled 5 charts

MET Positive

NCT01697072 2016-02-09

RILOMET-1

Phase 3 Terminated

Gastrointestinal

Stomach Neoplasms